Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria

Teerachat Sae-heng | Rajith Kumar Reddy Rajoli | Marco Siccardi | Juntra Karbwang | Kesara Na-Bangchang

Abstract
Patients with cerebral malaria with polymorphic Cytochrome P450 2C19 (CYP2C19) genotypes who receive concurrent treatment with quinine are at risk of inadequate or toxic therapeutic drug concentrations due to metabolic drug interactions. The study aimed to predict the potential dose regimens of quinine when coadministered with phenobarbital in adult patients with cerebral malaria and complications (e.g., lactic acidosis and acute renal failure) and concurrent with seizures and acute renal failure who carry wild-type and polymorphic CYP2C19. The whole-body physiologically based pharmacokinetic (PBPK) models for quinine, phenobarbital, and quinine–phenobarbital coadministration were constructed based on the previously published information using Simbiology®. Four published articles were used for model validation. A total of 100 virtual patients were simulated based on the 14-day and 3-day courses of treatment, using the drug–drug interaction approach. The predicted results were within 15% of the observed values. Standard phenobarbital dose, when administered with quinine, is suitable for all groups with single or continuous seizures regardless of CYP2C19 genotype, renal failure, and lactic acidosis. Dose adjustment based on area under the curve ratio provided inappropriate quinine concentrations. The recommended dose of quinine when coadministered with phenobarbital based on the PBPK model for all groups is a loading dose of 2000 mg intravenous (i.v.) infusion rate 250 mg/h followed by 1200 mg i.v. rate 150 mg/h. The developed PBPK models are credible for further simulations. Because the predicted quinine doses in all groups were similar regardless of the CYP2C19 genotype, genotyping may not be required.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Quinine is a drug of choice for severe malaria, including cerebral malaria, in cases when injectable artesunate and/or parenteral artemether are not available.
Phenobarbital is the standard treatment for cerebral malaria with concurrent seizures. Patients with cerebral malaria with polymorphic Cytochrome P450 2C19 (CYP2C19) genotypes who receive concurrent treatment with quinine are at risk of inadequate or toxic therapeutic drug concentrations as a result of metabolic drug interactions.

**WHAT QUESTION DID THIS STUDY ADDRESS?**

Does patients carrying polymorphic CYP2C19 with cerebral malaria with concurrent seizures require quinine-phenobarbital co-administered dose optimization? If so, what are the optimal dose regimens of both drugs when coadministered?

**WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**

The recommended dose of quinine and phenobarbital coadministration with phenobarbital based on the physiologically based pharmacokinetic (PBPK) model for all patients is a loading dose of 2000 mg i.v. infusion rate 250 mg/h followed by 1200 mg i.v. rate 150 mg/h. CYP2C19 genotyping and phenobarbital dose optimization are not required when coadministered with quinine.

**HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?**

The developed PBPK models are credible for further simulations of optimal dose regimens of quinine in patients with cerebral malaria with concurrent seizures and complications.

---

**INTRODUCTION**

Cerebral malaria remains a high burden neurological problem not only in children aged younger than 5 years but also in adults.1-3 Quinine is a drug of choice for severe malaria, including cerebral malaria in cases when injectable artesunate and/or parenteral artemether are not available (the recommended regimen is a loading dose of 20 mg/kg salt intravenous [i.v.] infusion for 4 h followed by 10 mg kg⁻¹ salt i.v. infusion for 4 h given every 8 h).4 Phenobarbital, a cost-effective antiepileptic drug, is the standard treatment for cerebral malaria with concurrent seizures (the recommended regimen is a loading dose of 15 mg/kg given i.v. infusion for 30 min followed by 1-3 mg kg⁻¹ given i.v. infusion for 30 min every 12 h).5,6 Phenobarbital-induced severe cutaneous adverse reactions are, however, of critical concern for clinical use of this drug.7 Information on the contribution of host genetics on such reactions in adult patients with cerebral malaria with concurrent seizures has been limited. Because phenobarbital induces the xenobiotic drug-metabolizing cytochrome P450 (CYP450) enzymes, the situation is further complicated when it is coadministered with drugs that are also metabolized by CYP450 enzymes. Phenobarbital is metabolized mainly in the livers by the polymorphic CYP450 isoforms: CYP2C98,9 (fraction of metabolized [fm] of CYP2C9 or fm,CYP2C9 = 0.1) and CYP2C198,9 (fm,CYP2C19 = 0.9). Quinine, on the other hand, is metabolized by CYP3A4 and uridine diphosphateglucuronosyltransferase1A1 (UGT1A1)10 (fm,CYP3A4 = 0.44 and fm,UGT1A1 = 0.56). The activities of both CYP3A4 and UGT1A1 enzymes are induced by phenobarbital.11,12 In addition, phenobarbital also induces CYP1A2, CYP2B1, CYP2B2, CYP2B6, CYP2C9, UGT1A4, UGT1A8, and UGT1A9.13,14 Patients with cerebral malaria with polymorphic CYP2C19 genotypes (altered phenobarbital clearance) who receive concurrent treatment with quinine are, therefore, at risk of inadequate or toxic therapeutic drug concentrations as a result of metabolic drug interactions.

In addition, quinine is a narrow therapeutic drug (therapeutic range 10–20 mg L⁻¹, therapeutic index 2).15 To our knowledge, there have been a few reports on the optimal phenobarbital dose for patients with epilepsy,8,9 but not for patients with cerebral malaria with seizures who carry polymorphic CYP2C19 as well as the wild-type genotypes. Also, the optimal dose(s) of quinine when coadministered with phenobarbital has never been reported in this group of patients. This is of concern as approximately 17.3% of adult patients with malaria had severe malaria, where 70.7% of the patients developed convulsions and the overall mortality rate was up to 14% of severe malaria cases.16 Physiologically based pharmacokinetic (PBPK) modeling and simulation are accepted by various regulatory authorities as a promising tool to support dose optimization in the clinical phase of drug development, particularly for the investigation of drug–drug interactions (DDIs) and non-DDIs.17 The present study aimed to apply PBPK modeling and simulation for the optimization of quinine and phenobarbital coadministration in adult patients with cerebral malaria with concurrent seizures. The optimal dose was...
predicted with consideration of genetic polymorphisms of CYP2C19, malarial complications (i.e., lactic acidosis and acute renal failure), and the propensity of DDIs.

METHODS

Model construction

Whole-body PBPK models for quinine and phenobarbital (alone and coadministration) were constructed based on the previously published information using Simbiology® (version 5.8.2), the product of MATLAB® (version 2019a; MathWorks, Natick, MA). The physicochemical and biochemical properties (model parameters) of each drug, including human physiological parameters, were obtained from the published articles and are available in the supplementary material of this article. Because quinine is a CYP3A4 inhibitor, the inhibitor constant was taken into account for model construction. Model assumptions included, blood-flow limited, absence of enterohepatic recirculation, and absence of 3-hydroxyquinine (metabolite) on quinine disposition.

Model validation

Four published articles for quinine and one article for phenobarbital were used for model validation. The published data were extracted using Plot digitizer® version 2.6.8 (Free Software Foundation, Inc., Boston, MA). The area under the plasma concentration–time curve (AUC) was calculated using the trapezoidal rule. The simulated results from the developed models were compared against the published data using the accepted criterion, that is, absolute average-fold errors (AAFEs) of ±2-fold. However, as quinine is a drug with a narrow therapeutic index, the AAFE used in this article was reduced to ±1.25-fold. The following is the mathematical equation for AAFEs:

\[ \text{AAFEs} = 10^{\frac{1}{n} \sum_{i=1}^{n} \left( \frac{\text{prediction}_{i} - \text{observation}_{i}}{\text{observation}_{i}} \right)} \]

where \( n \) is the number of observed pharmacokinetic parameters, the prediction is the simulated results from the developed model, and the observation is the published clinical data.

Sensitivity analysis

Sensitivity analysis was performed to determine the effect of the changes in model parameters on the clearance during the first 72 h following the i.v. regimen of phenobarbital and quinine–phenobarbital coadministration (DDI model). The model parameters for sensitivity analysis of the phenobarbital included a fraction of unbound phenobarbital (\( f_u \)), acid dissociation constant (pKa) of phenobarbital, LogP of phenobarbital, blood-to-plasma ratio (\( R_{bp} \)) of phenobarbital, \( f_{m,\text{CYP2C19}} \), and \( f_{m,\text{CYP2C9}} \), maximal effect at high concentrations (\( E_{\text{max}} \)) of CYP2C19, half-maximal effective concentrations (EC50) of CYP2C19, and hepatic blood flow (QHep). The model parameters for quinine (quinine–phenobarbital model) included \( f_u \) of quinine, acid dissociation constant (pKa) of quinine, LogP of quinine, \( R_{bp} \) of quinine, \( f_{m,\text{CYP3A4}} \), \( f_{m,\text{UGT1A1}} \), \( E_{\text{max}} \) of CYP2C19, UGT1A1, CYP3A4, and EC50 of CYP2C19, UGT1A1, CYP3A4, QHep, and the relative effect of CYP2C19 polymorphisms (wild-type, 2C19*1/*2, 2C19*1/*3, 2C19*2/*2, and 2C19*3/*3). The effect of the changes in model parameters on the clearance was determined by the change of each model parameter within ±20%. The following is the mathematical equation for sensitivity analysis:

\[ \text{Sensitivity coefficient} = \frac{\% \text{VY}}{\% \text{VX}} \]

where \%VY is the percent change of the clearance, and \% VX is the percent change of the model parameters.

Virtual population

A total of 100 virtual patients (50 males and 50 females aged 18–60 years and weighing 60 kg during the fasting state) were simulated in (i) seizure patients with polymorphic CYP2C19 (phenobarbital model), (ii) patients with cerebral malaria (quinine model), (iii) patients with cerebral malaria with concurrent seizures and polymorphic CYP2C19 (DDI model), and (iv) patients with cerebral malaria with concurrent seizures and acute renal failure (corrected with lactic acidosis) and polymorphic CYP2C19. The intrinsic clearance of phenobarbital in each genotype was obtained from the published clinical data for the wild-type CYP2C19*1/*1 (extensive metabolizer [EM]), CYP2C19*1/*2 (intermediate metabolizer [IM]), and CYP19*1/*3, CYP2C19*2/*2, or CYP2C19*3/*3 (poor metabolizer [PM]). The intrinsic clearance values in CYP2C19*1/*2 (IM) and CYP2C2C19*1/*3 or CYP2C19*2/*2 or CYP2C19*3/*3 (PM) were estimated as a relative clearance compared with wild-type. Acute renal failure or acute kidney injury (AKI) was classified based on the risk, injury, failure, loss of kidney function and end-stage kidney disease (RIFLE) criteria, that is, AKI (≤25% decrease of estimated glomerular filtration rate [eGFR]), RIFLE-R (risk; >25%–50% decrease of eGFR), RIFLE-I
Quinine dose regimen used in simulations

The standard regimen of quinine for severe malaria is the loading dose of 20 mg kg\(^{-1}\) (1000 mg base total dose for an average body weight of 60 kg) i.v. infusion for 4 h followed by the maintenance dose of 10 mg kg\(^{-1}\) (500 mg base total dose for an average body weight of 60 kg) i.v. infusion for 4 h given three times daily for 72 h (assuming that the patients respond to quinine treatment).\(^2\)

DDI model simulations

Simulation based on standard DDI study approach

For the standard DDI study approach, plasma concentration–time profiles of phenobarbital and quinine following the coadministration of the standard dose regimen of phenobarbital and quinine were simulated. Phenobarbital is given at 1.5 mg kg\(^{-1}\) day\(^{-1}\) (1–3 mg kg\(^{-1}\) day\(^{-1}\)) or 90 mg total dose for an average body weight of 60 kg with i.v. infusion for 30 min for 17 consecutive days. The standard dose regimen of quinine for 3 days (described previously) was given on day 14 of phenobarbital administration when steady-state plasma concentration was achieved.

Simulation based on actual clinical approach

For the PBPK simulation based on an actual clinical use approach, two simulated scenarios were applied with the total simulation time of 72 h. Scenario I applies to patients who have only a single seizure; phenobarbital (15 mg kg\(^{-1}\) or 900 mg total dose for an average body weight of 60 kg with i.v. infusion for 30 min) is given as a single dose 6 h after the first dose of quinine (average time of occurrence of seizure after admission).\(^42\) Scenario II applies to patients who have continuous seizures; phenobarbital at a loading dose of 15 mg kg\(^{-1}\) or 900 mg total dose for an average body weight of 60 kg with i.v. infusion for 30 min followed by the maintenance dose of 1.5 mg kg\(^{-1}\) day\(^{-1}\) (1–3 mg kg\(^{-1}\) day\(^{-1}\)) or 90 mg total dose for an average body weight of 60 kg with i.v. infusion for 30 min\(^42\) is given every 24 h, starting 6 h after the first dose of quinine until 72 h. The time of simulation and seizure frequency was based on a previous clinical report.\(^43\) The predicted optimal dosage regimens were presented as the amount of quinine base.

Criteria for optimal dose regimens

All regimens for quinine and phenobarbital were evaluated based on the criteria for optimal dose regimens. The optimal dose regimens of quinine for adult patients with cerebral malaria with seizures were proposed based on the therapeutic range of quinine, that is, maximal plasma concentration ($C_{\text{max}}$) $\leq$ 20 mg L\(^{-1}\) and minimal plasma concentration ($C_{\text{min}}$) $\geq$ 10 mg L\(^{-1}\).\(^15\) The optimal dosage of phenobarbital was proposed based on the therapeutic range of phenobarbital, that is, $C_{\text{max}}$ $\leq$ 40 mg L\(^{-1}\) and $C_{\text{min}}$ $\geq$ 15 mg L\(^{-1}\).\(^42\) The predicted pharmacokinetic parameters are presented as mean ± standard deviation (SD).

RESULTS

Model validation

The AAFEs for overall (both quinine and phenobarbital), quinine, and phenobarbital ranged from 1.08 ± 0.07,\(^36\) 1.07 ± 0.076,\(^32,36–38\) and 1.13,\(^39\) respectively. The overall AAFEs were within accepted ranges\(^40\) (Table S1). In addition, the overall errors were within 20% of the published data. The virtual predictive checks between the predicted results and published data are shown in the supplementary material file (Figure S1).

Sensitivity analysis

None of the sensitivity coefficient analysis values for phenobarbital clearance (phenobarbital model) in the wild-type CYP2C19EM, CYP2C19*1/*3PM, and CYP2C19PM were lower than 1 (Figure S2a,b,d). However, the coefficients in 3 of 18 in CYP2C19*1/*2IM were higher than 1 (Figure S2c). The visual comparative figures between CYP2C19EM (wild-type) and CYP2C19PM are shown in Figure S2e. For quinine (DDI model), only 2 of 34 model parameters in Scenario I were higher than 1 (Figure S3). The sensitivity coefficient over 1 indicates the high sensitivity of quinine clearance in the DDI model to these model parameters.

Simulation of standard dose regimen of phenobarbital in patients with seizures with polymorphic CYP2C19

Simulation based on standard DDI study approach

Results of the simulation of potential dose regimens (multiple dosing) of phenobarbital ($C_{\text{max}}$, $C_{\text{min}}$, and clearance)
in patients with wild-type *CYP2C19*EM and *CYP2C19*IM (*CYP2C19*1/*2 and *CYP2C19*1/*3) and *CYP2C19*PM are summarized in Table S2. Phenobarbital plasma concentrations for individuals with all *CYP2C19* genotypes are shown in Figure S4A–D). The average values of all parameters in all genotypes were within the therapeutic range.

Simulation based on actual clinical use only

Results of the simulation of potential dose regimen (single and multiple dosing) of phenobarbital (C\text{max}, C\text{min}, and clearance) in patients with *CYP2C19*EM, *CYP2C19*IM, and *CYP2C19*PM are summarized in Table S3. Phenobarbital plasma concentrations for all genotypes are shown in Figure S5 and Figure S6 for Scenarios I and II, respectively. The average values in all genotypes were within the therapeutic range.

Simulation of the potential dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and polymorphic *CYP2C19*

Results (C\text{min}, C\text{max}, area under the curve ratio [AUCR], and C\text{max} ratio) of the simulation of the standard dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures (Scenario I, single seizure; Scenario II, multiple seizures) and polymorphic *CYP2C19* based on the standard DDI and actual clinical use study approaches are summarized in Table S4.

Simulation based on standard DDI study approach

The standard dose regimen of quinine did not provide optimal plasma drug concentrations when coadministered with phenobarbital (C\text{min} < 10 mg L\text{−1}; Table S4). The initial regimen (Regimen 1: a loading dose of 2000 mg i.v. infusion for 4 h followed by maintenance doses of 1000 mg i.v. infusion for 4 h given three times a day) in patients with wild-type and polymorphic *CYP2C19* provided a twofold increase of quinine concentrations compared with standard quinine regimen. Regimen 1 provided C\text{max} exceeding 20 mg L\text{−1} but C\text{min} less than 10 mg L\text{−1} both in wild-type and polymorphic *CYP2C19* (Figure S7A and Figure S6B–D for *CYP2C19*EM, *CYP2C19*1/*2, and *CYP2C19*1/*3, *CYP2C19*2/*2, or *CYP2C19*3/*3, respectively). The time to reach therapeutic concentration ranged from 2 to 3 h. Another subsequent dose regimen was simulated (Regimen 2: a loading dose of 2000 mg i.v. for 8 h followed by maintenance doses of 1200 mg continuous infusion until day 3 [72 h]). Plasma quinine concentration-time profiles in are shown in Figure 1A–D for the wild-type *CYP2C19*EM, *CYP2C19*1/*2IM, and

![Figure 1](Prediction of quinine dose Regimen 2 in all genotypes based on a standard drug–drug interaction (DDI) study approach. CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19)
Simulation based on actual clinical use study approach

The standard dose regimen of quinine provided inappropriate plasma concentrations when coadministered with phenobarbital ($C_{\text{min}} < 10\ \text{mg L}^{-1}$; Table S4). The twofold increase of quinine standard dose regimen (based on AUCR; Regimen 1: a loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. for 4 h given three times a day) provided $C_{\text{max}}$ exceeding 20 mg L$^{-1}$ and $C_{\text{min}}$ less than 10 mg L$^{-1}$ in all genotypes in both scenarios. Plasma quinine concentration-time profiles in Scenarios I and II in the wild-type CYP2C19EM, CYP2C19*1/*2IM, and CYP2C19PM are shown in Figure S8 and Figure S9, respectively. Another subsequent dose regimen for Scenario I (single seizure) and Scenario II (multiple seizures) were simulated (Regimen 2: a loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. continuous infusion until day 3 [72 h]). Plasma quinine concentration-time profiles for wild-type and polymorphic CYP2C19 in Scenarios I and II are presented in Figure 2 and Figure 3, respectively. The pharmacokinetic parameters ($C_{\text{max}}$, $C_{\text{min}}$, and clearance) for Regimens 1 and 2 are summarized in Tables 1 and 2, respectively. Time to reach therapeutic quinine levels ranged from 4 to 6 h.

**DISCUSSION**

The current study successfully developed the DDI PBPK models. Although the sensitivity coefficients of some parameters were greater than 1, these parameters were obtained from experimental studies with low variability.

---

**FIGURE 2** Prediction of quinine dose regimens in polymorphic CYP2C19 based on actual clinical use approach (Regimen 2; Scenario I). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19)
FIGURE 3  Prediction of quinine dose regimens in polymorphic CYP2C19 based on actual clinical use approach (Regimen 2; Scenario II). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19.

TABLE 1  Prediction of quinine dose regimens when coadministered with phenobarbital based on Scenario I

| Regimen                          | $C_{\text{max}}$ (mg L$^{-1}$) | $C_{\text{min}}$ (mg L$^{-1}$) | Clearance (L h$^{-1}$) |
|---------------------------------|-------------------------------|-------------------------------|-----------------------|
| CYP2C19EM ($\text{CYP2C19^{*1/*1}}$) |                               |                               |                       |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | $23.92 \pm 3.32$ | $9.13 \pm 3.65$ | $9.61 \pm 2.82$ |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | $17.33 \pm 2.99$ | $15.07 \pm 3.92$ | $10.19 \pm 2.78$ |
| CYP2C19IM ($\text{CYP2C19^{*1/*2}}$) |                               |                               |                       |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | $23.48 \pm 3.97$ | $8.97 \pm 3.02$ | $10.41 \pm 3.17$ |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | $17.33 \pm 3.58$ | $14.23 \pm 4.15$ | $10.36 \pm 3.11$ |
| CYP2C19PM ($\text{CYP2C19^{*1/*3}}$) |                               |                               |                       |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | $23.32 \pm 3.33$ | $9.03 \pm 3.38$ | $10.18 \pm 3.03$ |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | $17.18 \pm 3.26$ | $14.34 \pm 4.21$ | $10.40 \pm 3.24$ |
| CYP2C19EM ($\text{CYP2C19^{*2/*2} or CYP2C19^{*3/*3}}$) |                               |                               |                       |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | $23.50 \pm 3.32$ | $8.97 \pm 3.66$ | $10.05 \pm 3.21$ |
| Regimen 2 (loading dose of 2000 mg i.v. infusion or 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | $17.59 \pm 2.49$ | $14.37 \pm 4.12$ | $9.71 \pm 2.25$ |

Note: Data are presented as mean ± SD.

Abbreviations: CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; $C_{\text{max}}$, peak plasma concentration; $C_{\text{min}}$, minimal plasma concentration; EM, extensive metabolizer; i.v., intravenous; PM, poor metabolizer.
TABLE 2 Prediction of quinine dose regimens when coadministered with phenobarbital based on Scenario II

| Regimen | Cmax (mg L⁻¹) | Cmin (mg L⁻¹) | Clearance (L h⁻¹) |
|---------|---------------|---------------|------------------|
| CYP2C19EM (CYP2C19*1/*1) | | | |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | 23.73 ± 3.12 | 8.1 ± 3.29 | 9.94 ± 2.72 |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | 17.87 ± 3.59 | 14.00 ± 4.45 | 9.99 ± 2.69 |
| CYP2C19IM (CYP2C19*1/*2) | | | |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | 23.46 ± 3.18 | 8.40 ± 2.87 | 10.17 ± 2.83 |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | 17.42 ± 3.65 | 14.01 ± 4.94 | 10.53 ± 3.30 |
| CYP2C19PM (CYP2C19*1/*3) | | | |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | 23.38 ± 3.17 | 8.25 ± 3.16 | 10.47 ± 3.00 |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | 17.67 ± 3.37 | 13.64 ± 3.93 | 10.28 ± 3.09 |
| CYP2C19EM (CYP2C19*2/*2 or CYP2C19*3/*3) | | | |
| Regimen 1 (loading dose of 2000 mg i.v. infusion for 4 h followed by 1000 mg i.v. infusion for 4 h [given every 8 h daily]) | 23.38 ± 3.17 | 8.25 ± 3.16 | 10.47 ± 3.00 |
| Regimen 2 (loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. infusion [given every 8 h daily]) | 17.37 ± 2.88 | 13.68 ± 3.94 | 10.34 ± 2.82 |

Note: Data are presented as mean ± SD.
Abbreviations: CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; Cmax, peak plasma concentration; Cmin, minimal plasma concentration; EM, extensive metabolizer; i.v., intravenous; PM, poor metabolizer.

FIGURE 4 Prediction of quinine dose regimens based on actual clinical use approach (Scenario I) in patients with cerebral malaria with concurrent seizures and acute renal failure (corrected with lactic acidosis) who carry polymorphic CYP2C19EM (Regimen 2). CYP2C19EM, extensive metabolizer of CYP2C19; CYP2C19PM, poor metabolizer of CYP2C19; CYP2C19IM, intensive metabolizer of CYP2C19; eGFR, estimated glomerular filtration rate; RIFLE-F, risk, injury, failure, loss of kidney function and end-stage kidney disease–failure; RIFLE-I, risk, injury, failure, loss of kidney function and end-stage kidney disease–injury; RIFLE-R, risk, injury, failure, loss of kidney function and end-stage kidney disease–risk.
The DDI PBPK models are therefore credible. Results of this study based on PBPK modeling and simulation raise a concern about the potential DDIs between quinine and phenobarbital when were coadministered in patients with cerebral malaria with concurrent seizures. The conventional dose adjustment based on the AUCR of both drugs in different clinical scenarios may provide suboptimal dose regimens with inadequate trough plasma levels, which will pose the patients at risk of treatment failure and/or severe complications. The PBPK modeling approach, on the other hand, has proved a promising tool for dose optimization of quinine and phenobarbital coadministration.

**Potential phenobarbital dose regimens in patients with seizures with polymorphic CYP2C19**

Simulation of the optimal phenobarbital dose regimens in patients with seizures who carry polymorphic CYP2C19 was investigated using dose regimens based on the two approaches, that is, the standard DDI study approach (at steady state of phenobarbital level) and the actual clinical use study approach (Scenario I for single seizure and Scenario II for continuous seizures). Results supported the previous report of the decrease in total clearance of phenobarbital by 1% and 21% and 27% in patients carrying the CYP2C19*1/*2IM, CYP2C19*1/*3PM, and CYP2C19PM (*2/*2 or *3/*3) genotypes, respectively. The reported frequencies of the wild-type, CYP2C19EM, and CYP2C19PM genotypes in the Thai population are 42%, 2.8%, and 13%, respectively. Based on the results of PBPK modeling using both the DDI and actual clinical use study approaches, however, dosage adjustment of phenobarbital may not be required as plasma drug concentrations were maintained within the therapeutic range, that is, $C_{\text{max}} \leq 40$ mg L$^{-1}$ and $C_{\text{min}} \geq 15$ mg L$^{-1}$. The proposed phenobarbital dosage regimens are optimal for the treatment of patients with single seizure (single dose of 900 mg or 15 mg kg$^{-1}$) as well as patients with cerebral malaria who have continuous seizures (a loading dose of 15 mg kg$^{-1}$ day$^{-1}$ followed by 1.5 mg kg$^{-1}$ day$^{-1}$ once daily) regardless of patients’ CYP2C19 genotypes. Genotyping is therefore not necessary, which is practical both in developed and developing countries. Also, the advantage of...
using phenobarbital over other anticonvulsants is its relatively low cost.\(^5\)

**Potential quinine dose regimens when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and polymorphic CYP2C19**

Similarly to phenobarbital, simulation of the potential quinine dose regimens in patients with concurrent cerebral malaria and seizures with polymorphic CYP2C19 were investigated using dose regimens based on the standard DDI study and actual clinical use (Scenarios I and II) study approaches. Dose optimization based on AUCR yielded undesirable plasma quinine concentrations when coadministered with phenobarbital. The recommended quinine dosage regimen obtained from the standard DDI approach or actual clinical study use approach was similar. Therefore, the standard DDI approach used could be satisfactorily applied in the real clinical scenarios.

**Simulation based on standard approach**

The proposed quinine dosage Regimen 2 provided adequate \(C_{\text{min}}\) above 10 mg L\(^{-1}\) and \(C_{\text{max}}\) under 20 mg L\(^{-1}\) in wild-type genotype and polymorphic CYP2C19 (Figure 1A–D). Therefore, this regimen was considered as the recommended dosage regimen of quinine when coadministered with phenobarbital because it provided plasma quinine concentrations within the therapeutic range. It is noted, however, that the infusion duration of 8 h (continuous infusion) might result in the delay of time to reach therapeutic level compared with the recommended standard regimen (4–6 and 2–3 h for the potentially recommended and standard regimen, respectively). Because the critical period for treatment of patients with cerebral malaria is during the first 24 h,\(^31\) such a delay is unlikely to pose the patients at risk of complicated manifestation or death.

**Simulation based on actual clinical use study approach**

Optimal \(C_{\text{max}}\) and \(C_{\text{min}}\) of quinine were achieved with adequate plasma concentrations following the proposed quinine dose regimen (Regimen 2) when coadministered with phenobarbital in both clinical scenarios (Scenario I for single seizure and Scenario II for continuous seizures) using PBPK modeling and simulation, but not the AUCR, (Figure 2A–D for Scenario I and Figure 3A–D for Scenario II). This quinine regimen can be coadministered with phenobarbital without consideration of CYP2C19 genotypes because plasma quinine concentrations in patients with wild-type and polymorphic CYP2C19 were comparable. There is no influence of CYP2C19 genotypes on the inducing effect of quinine metabolism because the steady-state drug concentrations are not achieved with a short duration of phenobarbital dosing. It is noted that the recommended dose regimens of quinine and phenobarbital coadministration apply to patients with cerebral malaria with seizures who have normal hepatic function but not in those with impaired function. Therapeutic drug monitoring for quinine in those patients is recommended.

**Simulation of the potential dose of quinine when coadministered with phenobarbital in patients with cerebral malaria with concurrent seizures and acute renal failure with lactic acidosis**

The recommended quinine dosage regimen in patients with cerebral malaria with seizure without acute renal failure and lactic acidosis can be applied to patients who have acute renal failure and lactic acidosis because plasma quinine concentrations were within the therapeutic range (Figure 4 and Figure 5 for Scenarios I and II, respectively). Thus, no dosage adjustment was needed. It was noted for the absence of influence of the state of acute renal failure (decrease of eGFR) on plasma quinine concentrations due to low renal excretion of quinine and phenobarbital.

The limitations of the study include the exclusion of the contribution of P-glycoprotein transporter on quinine disposition (due to lack of information on in vitro studies) as well as the inhibitory effect of 3-hydroxyquinine metabolite on CYP3A4 activity. Nevertheless, the significant impacts of these two factors on quinine disposition are unlikely.\(^16\) Because of the limited information on phenobarbital i.v. infusion in patients, one publication in healthy volunteers was used for phenobarbital model validation. Relying on the data only from one publication may be insufficient for model validation. Malaria infection may change the pharmacokinetics of phenobarbital through alteration of \(f_u\), although there is no evidence to support such supposition. In addition, most sensitivity
coefficients of the model parameters used for construction of the phenobarbital PBPK models were lower than 1, indicating the insensitivity of the model to the changing of parameters.

In conclusion, PBPK modeling is a promising tool for dose optimization of quinine in patients with cerebral malaria in resource-limited countries. The developed PBPK models for phenobarbital and quinine–phenobarbital co-administration are reliable. They successfully predicted the optimal doses regimens of phenobarbital in patients with cerebral malaria with single or continuous seizures with no requirement of CYP2C19 genotyping. Dose adjustment based on PBPK modeling but not AUCR provided desirable plasma quinine concentrations. Dose adjustment of the standard regimen of phenobarbital is not required when coadministered with quinine. The proposed potential dose regimen for quinine when coadministered with phenobarbital for patients with a single seizure (Scenario I) and continuous seizures (Scenario II) in all malaria-endemic areas regardless of CYP2C19 genotypes is a loading dose of 2000 mg i.v. infusion for 8 h followed by 1200 mg i.v. continuous infusion until day 3 (72 h).

CONFLICT OF INTEREST

The authors declared no conflict of interest.

AUTHOR CONTRIBUTIONS

T.S., J.K., and K.N. wrote the manuscript. T.S., J.K., M.S., and K.N. designed the research. T.S., R.K.R.R., and M.S. performed research. T.S., R.K.R.R., M.S., and K.N. analyzed the data. T.S., R.K.R.R., and M.S. contributed new reagents/analytical tools.

REFERENCES

1. Durrani AB, Durrani IU, Abbas N, Jabeen M. Epidemiology of cerebral malaria and its mortality. J Pak Med Assoc. 1997;47(8):213-215.
2. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005;4(12):827-840.
3. Newton CR, Hien TT, White N. Cerebral malaria. J Neurol Neurosurg Psychiatry. 2000;69(4):433-441.
4. Ampadu HH, Asante KP, Bosomprah S, et al. Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda. Malar J. 2019;18(1):36.
5. Chisholm D, Who C. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis. Epilepsia. 2005;46(5):751-759.
6. Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev. 2000;2(2):CD002152.
7. Manuyakorn W, Siripool K, Kamchaisatian W, et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatr Allergy Immunol. 2013;24(3):299-303.
8. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000;55(11-12):821-825.
9. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. J Clin Pharm Ther. 2006;31(3):275-282.
10. Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O. Metabolism and elimination of quinine in healthy volunteers. Eur J Clin Pharmacol. 2003;59(5-6):423-427.
11. Ramirez J, Komoroski BJ, Mirkov S, et al. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genom. 2006;16(2):79-86.
12. Almond LM, Mukadam S, Gardner I, et al. Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos. 2016;44(6):821-832.
13. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2012;54(1):11-27.
14. Plummer S, Beaumont B, Elcombe M, et al. Species differences in phenobarbital-mediated UGT gene induction in rat and human liver microtissues. Toxicol Rep. 2020;9(8):155-161.
15. Verdier MC, Bentue-Ferrer D, Tribut O, Therap SFP. Therapeutic drug monitoring of quinine. Therapie. 2011;66(6):507-516.
16. Boushab BM, Salem MSOA, Boukhary AOMS, Parola P, Basco L. Clinical features and mortality associated with severe malaria in adults in southern Mauritania. Trop Med Infect Dis. 2021;6(1):1.
17. Shebley M, Sandhu P, Emami Riedmaier A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88-110.
18. Saeheng T, Na-Bangchang K, Siccardi M, Rajoli RKR, Karbwang J. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of quinine coadministered with ritonavir-boosted lopinavir. Clin Pharmacol Ther. 2019;107(5):1209-1220.
19. Rajoli RK, Back DJ, Rannard S, et al. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin Pharmacokinet. 2015;54(6):639-650.
20. US Food and Drug Administration. Qualaquin [product label]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021799s011lbl.pdf. Published 2013. Accessed June 25, 2019.
21. Bogura S, van Eijkeren J, Bos P, Zeilmaker M, Slob W. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol. 2012;42(9):751-767.
22. Silamut K, White NJ, Looareesuwan S, Warrell DA. Binding of quinine to plasma proteins in falciparum malaria. Am J Trop Med Hyg. 1985;34(4):681-686.
23. Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanised livers. Xenobiotica. 2019;49(6):678-687.
24. Vermet H, Raoust N, Ngo R, et al. Evaluation of normalization methods to predict CYP3A4 induction in six fully characterized cryopreserved human hepatocyte preparations and HepaRG cells. *Drug Metab Dispos*. 2016;44(1):50-60.

25. Supanaranond W, Davis TM, Pukrittayakamee S, et al. Disposition of oral quinine in acute falciparum malaria. *Eur J Clin Pharmacol*. 1991;40(1):49-52.

26. Strauch S, Dressman JB, Shah VP, Kopp S, Polli JE, Barends DM. Biowaiver monographs for immediate-release solid oral dosage forms: Quinine sulfate. *J Pharm Sci*. 2012;101(2):499-508.

27. Dua VK, Sarin R, Prakash A. Determination of quinine in serum, plasma, red blood cells and whole blood in healthy and Plasmodium falciparum malaria cases by high-performance liquid chromatography. *J Chromatogr*. 1993;614(1):87-93.

28. Ehrnebo M, Odar-Cederlof I. Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uremic patients. *Eur J Clin Pharmacol*. 1975;8(6):445-453.

29. Bender AD, Post A, Meier JP, Higson JE, Reichard G. Plasma protein binding of drugs as a function of age in adult human subjects. *J Pharm Sci*. 1975;64(10):1711-1713.

30. Shou M, Hayashi M, Pan Y, et al. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. *Drug Metab Dispos*. 2008;36(11):2355-2370.

31. Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. *Drug Metab Dispos*. 2011;39(7):1139-1148.

32. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. *Am J Med*. 1982;73(4):564-572.

33. Varma MV, Gardner I, Steyn SJ, et al. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BBDCS) in early drug discovery. *Mol Pharm*. 2012;9(5):1199-1212.

34. Zhao XJ, Ishizaki T. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. *Eur J Drug Metab Pharmacokinet*. 1999;24(3):272-278.

35. Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. *J Biochem Mol Toxicol*. 2009;23(1):43-58.

36. Salako LA, Sowunmi A. Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. *Eur J Clin Pharmacol*. 1992;42(2):171-174.

37. White NJ, Looareesuwan S, Warrell DA, et al. Quinine loading dose in cerebral malaria. *Am J Trop Med Hyg*. 1983;32(1):1-5.

38. Davis TM, White NJ, Looareesuwan S, Silamut K, Warrell DA. Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. *Trans R Soc Trop Med Hyg*. 1988;82(4):542-547.

39. Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. *J Clin Pharmacol*. 1982;22(2–3):141-148.

40. Saeheng T, Na-Bangchang K, Karbwang J. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. *Eur J Clin Pharmacol*. 2018;74(11):1365-1376.

41. Thanachartwet V, Desakorn V, Sahassananda D, Kyaw Win KK, Supaporn T. Acute renal failure in patients with severe falciparum Malaria: using the WHO 2006 and RIFLE criteria. *Int J Nephrol*. 2013;2013:841518.

42. Kokwaro GO, Ogutu BR, Muchohu SN, Otieno GO, Newton CR. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. *Br J Clin Pharmacol*. 2003;56(4):453-457.

43. Mohapatra MKD, Dash LK, Mishra NR, Agrawala RK. Profile of seizures in adult falciparum malaria and clinical efficacy of phenytoin sodium for control seizures. *Asian Pac J Trop Dis*. 2012;2(suppl 2):S558-S562.

44. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008;49(7):1239-1276.

45. Sukasem C, Tunthong R, Chamanphon M, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clotidagrel in patients with atherothrombotic-risk factors. *Pharmacogenomics Pers Med*. 2013;6:85-91.

46. Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. *Drug Metab Pharmacokinet*. 2010;25(6):531-538.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Sae-heng T, Rajoli RKR, Siccardi M, Karbwang J, Na-Bangchang K.

Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria. *CPT Pharmacometrics Syst Pharmacol*. 2022;11:104–115. doi:10.1002/psp4.12737